180 related articles for article (PubMed ID: 29685953)
1. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.
Shah NN; Ahn KW; Litovich C; Fenske TS; Ahmed S; Battiwalla M; Bejanyan N; Dahi PB; Bolaños-Meade J; Chen AI; Ciurea SO; Bachanova V; DeFilipp Z; Epperla N; Farhadfar N; Herrera AF; Haverkos BM; Holmberg L; Hossain NM; Kharfan-Dabaja MA; Kenkre VP; Lazarus HM; Murthy HS; Nishihori T; Rezvani AR; D'Souza A; Savani BN; Ulrickson ML; Waller EK; Sureda A; Smith SM; Hamadani M
Blood Adv; 2018 Apr; 2(8):933-940. PubMed ID: 29685953
[TBL] [Abstract][Full Text] [Related]
2. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
4. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis.
Shah NN; Ahn KW; Litovich C; Sureda A; Kharfan-Dabaja MA; Awan FT; Ganguly S; Gergis U; Inwards D; Karmali R; Lazaryan A; Lekakis L; Munshi P; Nathan S; Saad AA; Solh M; Steinberg A; Vij R; Wood WA; Fenske TS; Smith S; Hamadani M
Blood Cancer J; 2019 Dec; 9(12):97. PubMed ID: 31796726
[TBL] [Abstract][Full Text] [Related]
6. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.
Hale GA; Shrestha S; Le-Rademacher J; Burns LJ; Gibson J; Inwards DJ; Freytes CO; Bolwell BJ; Hsu JW; Slavin S; Isola L; Rizzieri DA; Gale RP; Laport GG; Montoto S; Lazarus HM; Hari PN
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1036-1043.e1. PubMed ID: 22155506
[TBL] [Abstract][Full Text] [Related]
7. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
Savani M; Ahn KW; Chen Y; Ahmed S; Cashen AF; Shadman M; Modi D; Khimani F; Cutler CS; Zain J; Brammer JE; Rezvani AR; Fenske TS; Sauter CS; Kharfan-Dabaja MA; Herrera AF; Hamadani M
Br J Haematol; 2022 Apr; 197(2):212-222. PubMed ID: 35106754
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Laport GG; Montoto S; Maloney DG; Lazarus HM
Biol Blood Marrow Transplant; 2013 May; 19(5):746-53. PubMed ID: 23380340
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Lazarus HM
Biol Blood Marrow Transplant; 2013 Apr; 19(4):625-31. PubMed ID: 23333532
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
Pollack SM; Steinberg SM; Odom J; Dean RM; Fowler DH; Bishop MR
Biol Blood Marrow Transplant; 2009 Feb; 15(2):223-30. PubMed ID: 19167682
[TBL] [Abstract][Full Text] [Related]
11. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN
J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210
[TBL] [Abstract][Full Text] [Related]
12. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
[TBL] [Abstract][Full Text] [Related]
14. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Ram R; Gooley TA; Maloney DG; Press OW; Pagel JM; Petersdorf SH; Shustov AR; Flowers ME; O'Donnell P; Sandmaier BM; Storb RF; Gopal AK
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1537-45. PubMed ID: 21536145
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.
Atallah E; Logan B; Chen M; Cutler C; Deeg J; Jacoby M; Champlin R; Nishihori T; Confer D; Gajewski J; Farnia S; Greenberg P; Warlick E; Weisdorf D; Saber W; Horowitz MM; Rizzo JD
JAMA Oncol; 2020 Apr; 6(4):486-493. PubMed ID: 31830234
[TBL] [Abstract][Full Text] [Related]
16. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
[TBL] [Abstract][Full Text] [Related]
17. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
[TBL] [Abstract][Full Text] [Related]
18. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.
Kyriakou C; Boumendil A; Finel H; Nn Norbert Schmitz ; Andersen NS; Blaise D; Chevallier P; Browne P; Malladi R; Niederwieser D; Pagliuca A; Kroschinsky F; Montoto S; Dreger P;
Biol Blood Marrow Transplant; 2019 Jan; 25(1):86-93. PubMed ID: 30219698
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
